• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Septerna, Inc. - Common Stock (NQ:SEPN)

    37.69 -0.46 (-1.22%)
    Streaming Delayed Price Updated: 2:14 PM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 127,732
    Open 38.15
    Bid (Size) 37.61 (200)
    Ask (Size) 37.76 (500)
    Prev. Close 38.15
    Today's Range 37.24 - 38.57
    52wk Range 11.98 - 51.10
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Septerna to Participate in Upcoming Investor Conferences
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
    From Septerna, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +34.7%
    +34.7%
    1 Month
    +7.7%
    +7.7%
    3 Month
    +25.7%
    +25.7%
    6 Month
    +31.6%
    +31.6%
    1 Year
    +205.4%
    +205.4%

    More News

    Read More
    News headline image
    Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
    From Septerna, Inc.
    Via Business Wire
    News headline image
    Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Present at Bank of America Securities Health Care Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Present at TD Cowen 46th Annual Health Care Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Participate in 8th Annual Evercore Healthcare Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Participate in Upcoming Investor Conferences
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead ↗
    Via MarketBeat
    Topics World Trade
    News headline image
    Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Participate in Upcoming Investor Conferences
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗
    Via Benzinga

    Frequently Asked Questions

    Is Septerna, Inc. - Common Stock publicly traded?
    Yes, Septerna, Inc. - Common Stock is publicly traded.
    What exchange does Septerna, Inc. - Common Stock trade on?
    Septerna, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Septerna, Inc. - Common Stock?
    The ticker symbol for Septerna, Inc. - Common Stock is SEPN on the Nasdaq Stock Market
    What is the current price of Septerna, Inc. - Common Stock?
    The current price of Septerna, Inc. - Common Stock is 37.69
    When was Septerna, Inc. - Common Stock last traded?
    The last trade of Septerna, Inc. - Common Stock was at 09/01/26 02:14 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.